Physician profile
Robert G Swanson
NPI 1114969144
$706.09
in general payments reported to CMS, 2019-2025
19 companies · $180 in 2025
The $180 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.44 · 2020: $17.44 · 2022: $87.09 · 2023: $216 · 2024: $158 · 2025: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $554.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $554.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $158.07 | 2023-2025 | Tecvayli, Erleada, Carvykti |
| Regeneron Healthcare Solutions, INC. | $66.43 | 2022-2025 | Libtayo |
| Merck Sharp & Dohme LLC | $53.82 | 2024-2025 | Keytruda, Lynparza |
| Astrazeneca Pharmaceuticals LP | $53.21 | 2022-2025 | Tagrisso, Enhertu |
| Medtronic Vascular, INC. | $47.44 | 2019 | |
| Novartis Pharmaceuticals Corporation | $47.20 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.30 | 2023-2025 | Alunbrig, Iclusig |
| Cook Medical LLC | $41.49 | 2023 | Cook |
| Incyte Corporation | $30.69 | 2023-2025 | Monjuvi, Pemazyre, Jakafi |
| Eisai INC. | $19.97 | 2022 | |
| Stemline Therapeutics INC. | $19.48 | 2025 | Orserdu |
| Lilly USA, LLC | $18.96 | 2025 | Verzenio, Jaypirca |
| Servier Pharmaceuticals LLC | $18.37 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.44 | 2020 | |
| Taiho Oncology, INC. | $16.98 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| G1 Therapeutics, INC. | $14.64 | 2023 | Cosela |
| Pharmacosmos Therapeutics INC. | $13.08 | 2024 | Cosela |
| Seagen INC. | $12.95 | 2023 | Adcetris |
| Sobi, INC | $12.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Swanson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.